open access
Effect of once-weekly subcutaneous darbepoetin administration on blood pressure, kidney function and quality of live in anemic predialysis patients with chronic kidney disease
open access
Abstract
Results After 10 weeks of darbepoetin alfa administration at the dose of 10 μg/week, hemoglobin serum level had increased over 11 g/dl in 15 patients. In the 3 patients serum hemoglobin level during the darbepoetin a treatment did not increased, in 4 out of 15 patients after 10 weeks of darbepoetin a treatment at the dose of 10 μg/week and in 7 after 15 weeks of the treatment at the dose of 7.5 μg/weeks hemoglobin serum level had increased over 13 g/dl. After 2 months without darbepoetin alfa treatment hemoglobin serum level had decreased but still maintain the target level of 11 g/dl. Darbepoetin alfa was well tolerated.
Conclusions Darbepoietin treatment did not change the blood pressure, significantly improved the quality of live but did not slow the progression of chronic kidney disease.
Abstract
Results After 10 weeks of darbepoetin alfa administration at the dose of 10 μg/week, hemoglobin serum level had increased over 11 g/dl in 15 patients. In the 3 patients serum hemoglobin level during the darbepoetin a treatment did not increased, in 4 out of 15 patients after 10 weeks of darbepoetin a treatment at the dose of 10 μg/week and in 7 after 15 weeks of the treatment at the dose of 7.5 μg/weeks hemoglobin serum level had increased over 13 g/dl. After 2 months without darbepoetin alfa treatment hemoglobin serum level had decreased but still maintain the target level of 11 g/dl. Darbepoetin alfa was well tolerated.
Conclusions Darbepoietin treatment did not change the blood pressure, significantly improved the quality of live but did not slow the progression of chronic kidney disease.
Keywords
anemia; darbepoetin α; chronic kidney disease; hypertension; quality of life
About this articleTitle
Effect of once-weekly subcutaneous darbepoetin administration on blood pressure, kidney function and quality of live in anemic predialysis patients with chronic kidney disease
Journal
Issue
Article type
Original paper
Pages
123-129
Published online
2007-05-18
Page views
470
Article views/downloads
1376
Bibliographic record
Nadciśnienie tętnicze 2007;11(2):123-129.
Keywords
anemia
darbepoetin α
chronic kidney disease
hypertension
quality of life
Authors
Maria Wanic-Kossowska
Andrzej Tykarski
Mikołaj Kobelski
Stanisław Czekalski